Marksans Pharma shines on reporting near three-fold jump in Q1 consolidated net profit
Marksans Pharma is currently trading at Rs. 316.05, up by 37.15 points or 13.32% from its previous closing of Rs. 278.90 on the BSE.
The scrip opened at Rs. 280.40 and has touched a high and low of Rs. 319.90 and Rs. 277.30 respectively. So far 1446137 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 319.90 on 12-Aug-2026 and a 52 week low of Rs. 156.00 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 319.90 and Rs. 266.80 respectively. The current market cap of the company is Rs. 14238.40 crore.
The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 23.66% and 32.47% respectively.
Marksans Pharma has reported 43.65% jump in its net profit at Rs 69.04 crore for the first quarter ended June 30, 2026 (Q1FY27) as compared to Rs 48.06 crore for the same quarter in the previous year. The total income of the company has increased by 5.26% at Rs 338.66 crore for Q1FY27 as compared to Rs 321.74 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported near three-fold jump in its net profit at Rs 157.17 crore for Q1FY27 as compared to Rs 58.32 crore for the same quarter in the previous year. The total income of the company has increased by 38.45% at Rs 866.20 crore for Q1FY27 as compared to Rs 625.63 crore for the corresponding quarter previous year.
